HUP0004896A1 - HIV-1 Tat és/vagy Nef fehérjéket tartalmazó fúziós fehérjék - Google Patents

HIV-1 Tat és/vagy Nef fehérjéket tartalmazó fúziós fehérjék

Info

Publication number
HUP0004896A1
HUP0004896A1 HU0004896A HUP0004896A HUP0004896A1 HU P0004896 A1 HUP0004896 A1 HU P0004896A1 HU 0004896 A HU0004896 A HU 0004896A HU P0004896 A HUP0004896 A HU P0004896A HU P0004896 A1 HUP0004896 A1 HU P0004896A1
Authority
HU
Hungary
Prior art keywords
protein
derivative
hiv
proteins
tat
Prior art date
Application number
HU0004896A
Other languages
English (en)
Inventor
Claudine Bruck
Stephane Andre Georges Godart
Martine Marchand
Original Assignee
Smithkline Beecham Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10819735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0004896(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biologicals S.A. filed Critical Smithkline Beecham Biologicals S.A.
Publication of HUP0004896A1 publication Critical patent/HUP0004896A1/hu
Publication of HUP0004896A3 publication Critical patent/HUP0004896A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A találmány tárgya az alábbi fehérjék bármelyikét tartalmazóoltóanyag-készítmény: (a) HIV Tat fehérje vagy egy származéka, amivagy (i) egy fúziós partnerhez, vagy (ii) egy HIV Nef fehérjéhez vagyannak egy származékához van kapcsolva; vagy (b) HIV Nef fehérje vagyegy származéka, ami vagy (i) egy fúziós partnerhez, vagy (ii) egy HIVTat fehérjéhez vagy annak egy származékához van kapcsolva; vagy (c)HIV Nef fehérje vagy egy származéka, ami egy HIV Tat fehérjéhez vagyannak egy származékához és egy fúziós partnerhez van kapcsolva. Atalálmány tárgyát képezi továbbá az ilyen fehérjét kódoló nukleinsavés egy, az említett nukleinsavval transzformált olyan gazdasejt,például a Pichia Pastoris<>, továbbá eljárások a fehérjeelőállítására. A találmány szerinti megoldás alkalmas HIV-fertőzéselleni védekezésre. Ó
HU0004896A 1997-09-26 1998-09-17 Fusion proteins comprising hiv-1 tat and/or nef proteins HUP0004896A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9720585.0A GB9720585D0 (en) 1997-09-26 1997-09-26 Vaccine
PCT/EP1998/006040 WO1999016884A1 (en) 1997-09-26 1998-09-17 Fusion proteins comprising hiv-1 tat and/or nef proteins

Publications (2)

Publication Number Publication Date
HUP0004896A1 true HUP0004896A1 (hu) 2001-04-28
HUP0004896A3 HUP0004896A3 (en) 2003-05-28

Family

ID=10819735

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004896A HUP0004896A3 (en) 1997-09-26 1998-09-17 Fusion proteins comprising hiv-1 tat and/or nef proteins

Country Status (28)

Country Link
EP (1) EP1015596B2 (hu)
JP (2) JP2001518300A (hu)
KR (1) KR100554487B1 (hu)
CN (1) CN1188519C (hu)
AR (2) AR017147A1 (hu)
AT (1) ATE338128T1 (hu)
AU (1) AU746564B2 (hu)
BR (1) BR9812547A (hu)
CA (1) CA2305013C (hu)
CO (1) CO4810339A1 (hu)
CZ (1) CZ302878B6 (hu)
DE (1) DE69835756T3 (hu)
DK (1) DK1015596T4 (hu)
ES (1) ES2272012T5 (hu)
GB (1) GB9720585D0 (hu)
HK (1) HK1030431A1 (hu)
HU (1) HUP0004896A3 (hu)
IL (1) IL135102A0 (hu)
NO (2) NO328824B1 (hu)
NZ (1) NZ503482A (hu)
PL (1) PL195243B1 (hu)
PT (1) PT1015596E (hu)
SA (1) SA98190877B1 (hu)
SI (1) SI1015596T2 (hu)
TR (1) TR200000864T2 (hu)
TW (1) TW499436B (hu)
WO (1) WO1999016884A1 (hu)
ZA (1) ZA988789B (hu)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
WO2000050077A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
JP2002541786A (ja) * 1999-04-12 2002-12-10 モデックス テラピューティク ソシエテ アノニム 遺伝子治療における使用のための一過性不死化細胞
ES2250151T3 (es) * 1999-06-29 2006-04-16 Glaxosmithkline Biologicals S.A. Uso de cpg como adyuvante de vacuna contra vih.
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
WO2001054719A2 (en) * 2000-01-31 2001-08-02 Smithkline Beecham Biologicals S.A. Vaccine for the prophylactic or therapeutic immunization against hiv
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
EP1279404A1 (en) * 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
NZ564586A (en) 2001-11-21 2009-09-25 Univ Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
KR100466382B1 (ko) * 2002-01-08 2005-01-14 주식회사 엘지생명과학 인간 면역 결핍 바이러스-1, -2 타입의 단백질이 융합된 재조합 콤보 단백질, 이의 생산방법, 이를 포함하는 벡터, 형질전환된 대장균 및 진단키트
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
CN1325512C (zh) 2002-05-16 2007-07-11 巴法里安诺迪克有限公司 Hiv调节/辅助蛋白的融合蛋白
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US7927580B2 (en) 2004-03-16 2011-04-19 Nanirx, Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0507003D0 (en) * 2005-04-06 2005-05-11 Molmed Spa Therapeutic
DE602006018768D1 (de) * 2005-10-18 2011-01-20 Nat Jewish Health Denver Konditionell immortalisierte adulte langzeit-stammzellen und verfahren zur herstellung und verwendung von solchen zellen
AU2008350937B2 (en) 2007-11-28 2014-10-09 The Trustees Of The University Of Pennsylvania Simian subfamily C adenovirus SAdV-31 and uses thereof
CN101883858B (zh) 2007-11-28 2015-07-22 宾夕法尼亚大学托管会 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用
WO2009136977A2 (en) 2008-03-04 2009-11-12 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
SG190661A1 (en) 2008-05-16 2013-06-28 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
AU2009274172B2 (en) 2008-07-21 2015-08-13 Htyr Acquisition Llc Differentiated anucleated cells and method for preparing the same
SG193831A1 (en) 2008-08-28 2013-10-30 Taiga Biotechnologies Inc Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
ES2552688T3 (es) 2008-10-31 2015-12-01 The Trustees Of The University Of Pennsylvania Adenovirus de simio con proteínas de la cápside hexónica de SAdV-46 y usos del mismo
CN102405057B (zh) 2009-03-23 2016-05-25 那尼尔科斯治疗公司 用免疫刺激性Hiv Tat衍生物多肽治疗癌症
WO2010138675A1 (en) 2009-05-29 2010-12-02 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
AU2011332025B2 (en) 2010-11-23 2015-06-25 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
EP2708561A4 (en) * 2011-03-15 2014-09-24 Univ Yonsei Iacf BIO-PIN
CN105473723A (zh) 2012-05-18 2016-04-06 宾夕法尼亚大学托管会 亚家族e猿腺病毒a1302、a1320、a1331和a1337及其用途
WO2014012090A1 (en) 2012-07-13 2014-01-16 The Broad Institute, Inc. Molecular sleds comprising a positively-charged amino acid sequence and a molecular cargo and uses thereof
SG11201500429QA (en) 2012-07-20 2015-03-30 Taiga Biotechnologies Inc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
EP3052127A1 (en) 2013-10-04 2016-08-10 PIN Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
KR102550926B1 (ko) 2014-05-13 2023-07-05 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 이중 항체 구축물을 발현하는 aav를 포함하는 조성물 및 이들의 용도
US11207421B2 (en) 2015-04-16 2021-12-28 The Research Foundation For The State University Of New York Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
JP6886406B2 (ja) * 2015-04-16 2021-06-16 ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク コバルトポルフィリン・リン脂質コンジュゲート及びポリヒスチジンタグを含むナノ構造体
EP3548425B1 (en) 2016-12-02 2023-03-29 Taiga Biotechnologies, Inc. Nanoparticle formulations
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
AU2022264509A1 (en) 2021-04-27 2023-12-14 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004686A1 (en) * 1992-08-21 1994-03-03 Biogen, Inc. Tat-derived transport polypeptides
GB9003010D0 (en) * 1990-02-09 1990-04-04 Glaxo Group Ltd Gene expression in yeast cells
JPH07502646A (ja) * 1991-10-21 1995-03-23 メディミューン，インコーポレーテッド リポタンパク質の分泌シグナルをコード化するｄｎａを含む細菌発現ベクター
JP3701966B2 (ja) * 1993-01-26 2005-10-05 ウェイナー，デービッド・ビー 遺伝物質送達のための組成物および方法
EP0814834B2 (fr) * 1995-03-08 2009-03-18 Neovacs Immunogenes denues de toxicite derivant d'une proteine de regulation retrovirale, anticorps diriges contre ces immunogenes, procede pour leur preparation et compositions pharmaceutiques les renfermant
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
AU1025599A (en) 1999-04-23
SI1015596T2 (sl) 2010-07-30
IL135102A0 (en) 2001-05-20
AR017147A1 (es) 2001-08-22
KR100554487B1 (ko) 2006-03-03
NO20001508D0 (no) 2000-03-23
PT1015596E (pt) 2006-12-29
DE69835756T2 (de) 2007-09-13
TW499436B (en) 2002-08-21
CN1188519C (zh) 2005-02-09
NZ503482A (en) 2001-09-28
AU746564B2 (en) 2002-05-02
CO4810339A1 (es) 1999-06-30
EP1015596B2 (en) 2010-04-14
EP1015596A1 (en) 2000-07-05
CA2305013C (en) 2008-04-08
KR20010024287A (ko) 2001-03-26
JP2009213492A (ja) 2009-09-24
HK1030431A1 (en) 2001-05-04
NO20076467L (no) 2000-05-18
PL195243B1 (pl) 2007-08-31
TR200000864T2 (tr) 2000-08-21
CZ20001091A3 (cs) 2000-09-13
EP1015596B1 (en) 2006-08-30
CN1279718A (zh) 2001-01-10
WO1999016884A1 (en) 1999-04-08
ES2272012T3 (es) 2007-04-16
BR9812547A (pt) 2000-07-25
DK1015596T4 (da) 2010-07-12
DE69835756D1 (de) 2006-10-12
DK1015596T3 (da) 2007-01-02
ATE338128T1 (de) 2006-09-15
CA2305013A1 (en) 1999-04-08
NO20001508L (no) 2000-05-18
GB9720585D0 (en) 1997-11-26
NO328824B1 (no) 2010-05-25
ES2272012T5 (es) 2010-07-06
PL339432A1 (en) 2000-12-18
HUP0004896A3 (en) 2003-05-28
AR080331A2 (es) 2012-03-28
ZA988789B (en) 2000-03-29
SA98190877B1 (ar) 2006-09-10
DE69835756T3 (de) 2010-09-30
CZ302878B6 (cs) 2012-01-04
JP2001518300A (ja) 2001-10-16
SI1015596T1 (sl) 2007-02-28

Similar Documents

Publication Publication Date Title
HUP0004896A1 (hu) HIV-1 Tat és/vagy Nef fehérjéket tartalmazó fúziós fehérjék
ATE380822T1 (de) Funf-helix protein
ATE286978T1 (de) Rekombinante hiv-2 antigenen, abgeleitete aus synthetischen dns
ES2009350A6 (es) Procedimiento para la preparacion de vectores de expresion que codifican una nueva proteina.
CY1108638T1 (el) Πρωτεϊνη συντηξης των hiv ρυθμιστικων/επικουρικων πρωτεϊνων
EP1050532A3 (en) Preparation of s,s and r,s amino acid isosteres
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
IL145884A0 (en) Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein
TR200501541T2 (tr) Leu-hirudinin e.coli ile kültür ortamında ayrışarak üretilmesinin sinyal sekansları
AU2002234863A1 (en) Denaturat stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same and their uses
HUP0301089A2 (hu) Dermális alkalmazási rendszerek aminolevulinsavhoz
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
ATE199394T1 (de) Gag-env fusion-antigen aus hiv
HUP0003327A2 (hu) Szőlőlevél-sodródást okozó vírus (2. típus) fehérjék és alkalmazásuk
ATE166390T1 (de) Anti-katze immundefiziensvirus (fiv) impfstoffe
SE9903534L (sv) Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
BR0211991A (pt) HormÈnio do crescimento humano modificado
HUP9702147A2 (hu) Humán DNáz I variánsok
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
HUP0100132A2 (hu) A béta-lipotropin és felhasználása
SE0100412D0 (sv) Novel human poly(A) polymerase
ECSP982804A (es) Beta- lipotropina y usos de la misma
TH13136EX (th) แอนติเจนของ hiv
AR003102A1 (es) Vacuna de env-glicoproteina para la proteccion de infeccion de htlv-i y ii

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished